Project Grant R01AG102693
- The National Institute on Aging awarded New York University School of Medicine $3,557,115 on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate the neurobiological mechanisms linking menopause and cognitive decline in women. The recipient will conduct a longitudinal study mapping neurobiological changes during the menopause transition in a cohort of 120 pre- and perimenopausal women aged 40–48 using state-of-the-art neuroimaging, plasma proteomics, and clinical...
- The National Institute on Aging awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $189,963 on July 1, 2026, under the Aging Research program (CFDA 93.866) to support research led by Dr. Carlisle investigating the contributions of biological sex and sex hormones to cognitive reserve across the cognitive spectrum of Alzheimer's disease. The research will assess how estrogen and sex differences affect Alzheimer's disease risk, with particular...
- The National Institute on Aging awarded the University of Southern California $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate how early-stage Alzheimer's disease disrupts coordinated release dynamics between acetylcholine and norepinephrine in the cortex and how this discoordination impairs cognitive performance. The research characterizes the evolution of coordinated cortical acetylcholine and norepinephrine release activity in vivo in wildtype mice,...
- The National Institute on Aging awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $3,558,232 under the Aging Research program (CFDA 93.866) on August 5, 2026, to conduct the WHIMSY-AD Study examining menopause and related midlife risk factors and their impact on later-life Alzheimer's disease pathology and cognition. The study recontacts 700 participants from the Women's Health Initiative Memory Study of Younger Women (WHIMSY), now aged 75–84 years,...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded the University of Southern California $4,055,366 under the Aging Research program (CFDA 93.866) to conduct a four-year research project examining the impact of circulating endocrine disrupting toxicants on cognition, brain activity, and Alzheimer's disease (AD) biomarkers across the menopausal transition. The project, which commenced on September 15, 2025, and concludes August 31, 2029, addresses a critical gap...
- The National Institute on Aging awarded Rosalind Franklin University of Medicine & Science $696,253 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how hormonal fluctuations during perimenopause alter hippocampal neural circuits and accelerate Alzheimer's disease pathology in female mice. The recipient will use 4-vinylcyclohexene diepoxide (VCD) to chemically induce ovarian failure in AppNLGF knock-in AD model mice, mimicking human perimenopause...
- The National Institute on Aging awarded the University of California, Los Angeles $623,176 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on modifiable risk factors for Alzheimer's disease and related dementias among individuals aged 90 and older. The research triangulates evidence across four data sources—the LifeAfter90 Study (1,397 participants, all aged 90), the 90+ Study (1,630 participants, all aged 90), the Health and Retirement Study (3,359...
- The National Institute on Aging awarded the University of California, Los Angeles $169,020 on August 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a clinical trial of repetitive transcranial magnetic stimulation (RTMS) targeting the posterior parietal lobe in Alzheimer's disease patients. The project, titled "Protocol for Maintaining and Improving Mental Status in Alzheimer's Disease (PROMIS-AD): A Study of Broad-Coil Parietal Repetitive Transcranial Magnetic...
- The National Institute on Aging, within the National Institutes of Health and the Department of Health and Human Services, awarded the University of California Irvine $739,365 on September 15, 2026, under the Aging Research program (CFDA 93.866, Project Grant R01AG098878) to develop and evaluate structure-guided active and passive beta-amyloid immunotherapies targeting early, non-fibrillar assemblies in Alzheimer's disease. The project develops vaccines and monoclonal antibodies directed against...
- The National Institute on Aging awarded The Regents of the University of California, San Francisco $902,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the steroid hormone androst-5-ene-3β,17β-diol (ADIOL) as a regulator of cognitive resilience and protection against age-related cognitive decline and Alzheimer's disease. The project conducts mechanistic studies in mice and correlative studies in humans to test the hypothesis that ADIOL, acting through...
The National Institute on Aging awarded the University of Southern California $5.945 million on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct the Alzheimer's Risk Intervention Trial with Estradiol (ARITE), a randomized, double-blinded, placebo-controlled investigation of menopausal hormone therapy effects on neuroimaging markers of Alzheimer's disease and related dementias risk in postmenopausal women. The trial enrolls 360 postmenopausal women and uses brain imaging to assess shorter-term menopausal hormone therapy effects on brain health and Alzheimer's disease risk, focusing on the hypothesis that menopausal hormone therapy administered within a critical window of six years after menopause will prevent or delay Alzheimer's disease onset in aging women. This work expands on prior menopausal hormone therapy trial success in reducing vascular risk. Performance occurs in Los Angeles, California. The period of performance runs from September 1, 2026, through August 31, 2031. The award is a Project Grant, a standard assistance type under the National Institute on Aging's mission to support biomedical and behavioral research directed toward prevention and treatment of Alzheimer's disease and related dementias.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $5.9m | 9/1/26 |